Targeted Delivery of Human VEGF Gene via Complexes of Magnetic Nanoparticle-Adenoviral Vectors Enhanced Cardiac Regeneration

Zhang, Yue; Li, Wenzhong; Ou, Lailiang; Wang, Weiwei; Delyagina, Evgenya; Lux, Cornelia A.; Sorg, Heiko; Riehemann, Kristina; Steinhoff, Gustav; Ma, Nan

doi:10.1371/journal.pone.0039490

Cited by 67 publications

(44 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assay for Binding of rZRANB2 to LPS, Lipid A, and BacteriaBoth rZRANB2 and BSA were individually biotinylated with biotinamidohexanoic acid N-hydroxysuccinimide ester (NHS-LC-biotin; HEOWNS Biochem Technologies, Tianjin, China) as described by Zhang et al (48). To verify the binding of rZRANB2 to LPS, 50 l of 80 g/ml LPS in 10 mM PBS, pH 7.4, was applied to each well of a 96-well microplate and air-dried at 25°C overnight.…”

Section: Isolation Of Lps-bound Proteins and Mass Spectrometricmentioning

confidence: 99%

Identification of the Zinc Finger Protein ZRANB2 as a Novel Maternal Lipopolysaccharide-binding Protein That Protects Embryos of Zebrafish against Gram-negative Bacterial Infections

Wang

et al. 2016

Journal of Biological Chemistry

View full text Add to dashboard Cite

Zinc finger ZRANB2 proteins are widespread in animals, but their functions and mechanisms remain poorly defined. Here we clearly demonstrate that ZRANB2 is a newly identified LPSbinding protein present abundantly in the eggs/embryos of zebrafish. We also show that recombinant ZRANB2 (rZRANB2) acts as a pattern recognition receptor capable of identifying the bacterial signature molecule LPS as well as binding the Gramnegative bacteria Escherichia coli, Vibrio anguilarum, and Aeromonas hydrophila and functions as an antibacterial effector molecule capable of directly killing the bacteria. Furthermore, we reveal that N-terminal residues 11-37 consisting of the first ZnF_RBZ domain are indispensable for ZRANB2 antimicrobial activity. Importantly, microinjection of rZRANB2 into early embryos significantly enhanced the resistance of the embryos against pathogenic A. hydrophila challenge, and this enhanced bacterial resistance was markedly reduced by co-injection of anti-ZRANB2 antibody. Moreover, precipitation of ZRANB2 in the embryo extracts by preincubation with anti-ZRANB2 antibody caused a marked decrease in the antibacterial activity of the extracts against the bacteria tested. In addition, the N-terminal peptide Z 1/37 or Z 11/37 with in vitro antibacterial activity also promoted the resistance of embryos against A. hydrophila, but the peptide Z 38/198 without in vitro antibacterial activity did not. Collectively, these results indicate that ZRANB2 is a maternal LPS-binding protein that can protect the early embryos of zebrafish against pathogenic attacks, a novel role ever assigned to ZRANB2 proteins. This work also provides new insights into the immunological function of the zinc finger proteins that are widely distributed in various animals.

show abstract

Section: Isolation Of Lps-bound Proteins and Mass Spectrometricmentioning

confidence: 99%

Identification of the Zinc Finger Protein ZRANB2 as a Novel Maternal Lipopolysaccharide-binding Protein That Protects Embryos of Zebrafish against Gram-negative Bacterial Infections

Wang

et al. 2016

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…-Magnetic nanobeads: have been employed to deliver adenoviral vectors encoding hVEGF to enhance transduction efficiency [69].…”

Section: Injectable Nanomaterialsmentioning

confidence: 99%

Materials for cardiac tissue engineering

Gálvez‐Montón¹,

Soler‐Botija²,

Roura³

et al. 2016

Nanomaterials and Regenerative Medicine

View full text Add to dashboard Cite

“…Zhang et al (94) applied externally controlled magnetic nanobeads conjugated to adenoviral vectors-encoded human vascular endothelial growth factor (VEGF) gene. Following intravenous administration, the nanobeads were accumulated in the myocardial region by external epicardial magnet, resulting in a good transduction efficiency and a strong VEGF gene expression in the ischemic zone of the heart.…”

Section: Myocardial Infarctionmentioning

confidence: 99%

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Cicha¹,

Garlichs²,

Alexiou³

2014

European Journal of Nanomedicine

View full text Add to dashboard Cite

Abstract:Recent years brought about a widespread interest in the potential applications of nanotechnology for the diagnostics and the therapy of human diseases. With its promise of disease-targeted, patient-tailored treatment and reduced side effects, nanomedicine brings hope for millions of patients suffering of non-communicable diseases such as cancer or cardiovascular disorders. However, the emergence of the complex, multicomponent products based on new technologies poses multiple challenges to successful approval in clinical practice. Regulatory and development considerations, including properties of the components, reproducible manufacturing and appropriate characterization methods, as well as nanodrugs' safety and efficacy are critical for rapid marketing of the new products. This review discusses the recent advances in cardiovascular applications of nanotechnologies and highlights the challenges that must be overcome in order to fill the gap existing between the promising bench trials and the successful bedside applications.

show abstract

Targeted Delivery of Human VEGF Gene via Complexes of Magnetic Nanoparticle-Adenoviral Vectors Enhanced Cardiac Regeneration

Cited by 67 publications

References 38 publications

Identification of the Zinc Finger Protein ZRANB2 as a Novel Maternal Lipopolysaccharide-binding Protein That Protects Embryos of Zebrafish against Gram-negative Bacterial Infections

Identification of the Zinc Finger Protein ZRANB2 as a Novel Maternal Lipopolysaccharide-binding Protein That Protects Embryos of Zebrafish against Gram-negative Bacterial Infections

Materials for cardiac tissue engineering

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Contact Info

Product

Resources

About